Background The estimation of risk of recurrence for patients with colon carcinoma must be
improved. A robust immune score quantification is needed to introduce immune parameters …

As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's
disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for …

BACKGROUND & AIMS: The anti–tumor necrosis factor (TNF) antibodies infliximab,
adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn's disease. Here, we …

Endometrial carcinoma (EC) molecular classification based on four molecular subclasses
identified in The Cancer Genome Atlas (TCGA) has gained relevance in recent years due to its …

Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE)
exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) …

PURPOSE The purpose of this study was to evaluate the prognostic value of Immunoscore
in patients with stage III colon cancer (CC) and to analyze its association with the effect of …

The emergence of novel immunomodulatory cancer therapies over the last decade, above
all immune checkpoint blockade, has significantly advanced tumor treatment. For colorectal …

Objective Several pathogenic roles attributed over the past two decades to either T helper (Th)1
or Th2 cells are increasingly becoming associated with interleukin (IL)-17 and most …

The Helicobacter pylori (Hp) type IV secretion system (T4SS) forms needle-like pili, whose
binding to the integrin-β 1 receptor results in injection of the CagA oncoprotein. However, the …

The fifth “Melanoma Bridge Meeting” took place in Naples, December 1–5th, 2015. The main
topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies …